Business
PAOG Sets 2021 Cannabis Biopharmaceutical Revenue Goals
PAOG Sets 2021 Cannabis Biopharmaceutical Revenue Goals.
About this update from Pao Group, Inc.
[{"type":"text","content":"\n\n\n\nPAOG Sets 2021 Cannabis Biopharmaceutical Revenue Goals\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\nPAOG Sets 2021 Cannabis Biopharmaceutical Revenue Goals\nPR Newswire\nSANDUSKY, OH, Jan. 14, 2021\n\n\n\nSANDUSKY, OH, Jan. 14, 2021 /PRNewswire/ -- PAO Group, Inc. (USOTC: PAOG) today published a management outlook for 2021 on the company's strategy to develop and monetize the cannabis assets acquired last year.  The strategic outlook is included in its entirety below:\nPAOG 2021 Cannabis Biopharmaceutical Strategic Outlook\nPAOG is a longtime participant in the cannabis sector working on initiatives to introduce cannabis treatments as alternatives to traditional pharmaceuticals, particularly where existing pharmaceutical treatments have potentially severe secondary ramifications as is the case with opioid based treatments.\nLast year, the company shifted its primary focus to the development biopharmaceutical treatments derived from cannabis.\nOn July 30, 2020, PAOG acquired RespRx from Kali-Extracts, Inc. (OTC Pink: KALY) RespRx is a cannabis treatment under development for Chronic Obstructive Pulmonary Disorder (COPD) derived from a patented cannabis extraction method - U.S. Patent No. 9,199,960 entitled \"METHOD AND APPARATUS FOR PROCESSING HERBACEOUS PLANT MATERIALS INCLUDING THE CANNABIS PLANT.\"\nPAOG also acquired a of hemp cultivation business from Puration, Inc. (USOTC: PURA).  This operation comes with existing sales activity and PAOG expects to report its first revenue from the acquisition in conjunction with the inclusion of Q4 2020 results into the overall 2020 financial report.\nSince the two acquisitions, PAOG has been working diligently to develop and execute upon a strategy to monetize the assets in a manner that acheives self-sustainable operations at the same time delivering optimal shareholder value.\nToward that end, PAOG has entered into three strategic partnerships.\nPAOG recently announced an engagement with Veristat, Inc., a contract research organization headquartered in Southborough Massachusetts. PAOG has engaged...